The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| XBIO | -50.6% | -90.47% | -37.51% | -100% |
| S&P | +15.66% | +85.04% | +13.1% | +286% |
Xenetic Biosciences, Inc. is a biopharmaceutical company engaged in the advancement of cell-based therapeutics to target the B-cell receptor on the surface of an individual patient’s malignant tumor cells. Its product pipeline includes XCart Platform and Polyxen. The company was founded on August 9, 2011 and is headquartered in Framingham, MA.
No news articles found for Xenetic Biosciences.
| Q3 2025 | YOY Change | |
|---|---|---|
| Revenue | $1.03M | 67.2% |
| Market Cap | $4.84M | -27.3% |
| Market Cap / Employee | $2.42M | 0.0% |
| Employees | 2 | -50.0% |
| Net Income | -$509.94K | -16.8% |
| EBITDA | -$544.73K | -9.1% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q3 2025 | YOY Change | |
|---|---|---|
| Net Cash | $4.12M | -39.7% |
| Inventory | 0 | 0.0% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $0.00K | 0.0% |
| Short Term Debt | $0.00K | 0.0% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -48.14% | -7.4% |
| Return On Invested Capital | -55.16% | 1.7% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$658.25K | -43.4% |
| Operating Free Cash Flow | -$658.25K | -43.4% |
| Metric | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | 0.87 | 0.67 | 1.18 | 1.09 | 21.70% |
| Price to Sales | 2.46 | 1.56 | 2.47 | 1.69 | -35.83% |
| Price to Tangible Book Value | 0.87 | 0.67 | 1.18 | 1.09 | 21.70% |
| Enterprise Value to EBITDA | 0.03 | 1.21 | -1.75 | -1.33 | -473.20% |
| Return on Equity | -50.1% | -53.2% | -51.8% | -57.4% | 26.26% |
| Total Debt | $0.00K | $0.00K | $0.00K | $0.00K | - |
No podcast episodes available.
No transcripts available.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
